His primary scientific interests are in Glioma, Cancer research, Internal medicine, Oncology and Temozolomide. His Glioma research includes themes of Angiogenesis, Paracrine signalling, Bioinformatics, DNA repair and Methyltransferase. His Cancer research research is multidisciplinary, incorporating perspectives in Apoptosis, Programmed cell death and CD8, Immune system.
His studies examine the connections between Internal medicine and genetics, as well as such issues in Anaplastic astrocytoma, with regards to Survival analysis. His work deals with themes such as Clinical trial, Pathology, Personalized medicine and DNA methylation, which intersect with Oncology. His Temozolomide research is multidisciplinary, incorporating elements of Bevacizumab and Chemoradiotherapy.
His primary areas of investigation include Glioma, Internal medicine, Cancer research, Oncology and Temozolomide. Within one scientific family, Wolfgang Wick focuses on topics pertaining to Magnetic resonance imaging under Glioma, and may sometimes address concerns connected to Nuclear medicine. His Internal medicine research includes elements of Surgery and Glioblastoma.
His work is dedicated to discovering how Cancer research, DNA methylation are connected with Methylation and other disciplines. His Oncology research is multidisciplinary, relying on both Randomized controlled trial and Chemotherapy. His Temozolomide study integrates concerns from other disciplines, such as Phases of clinical research, Clinical endpoint, Hazard ratio, Concomitant and O-6-methylguanine-DNA methyltransferase.
His primary areas of study are Glioma, Internal medicine, Cancer research, Oncology and DNA methylation. A large part of his Glioma studies is devoted to Temozolomide. In general Internal medicine, his work in Clinical trial and Hazard ratio is often linked to Isocitrate dehydrogenase linking many areas of study.
His research investigates the connection between Cancer research and topics such as Brain metastasis that intersect with problems in Cancer cell. His research investigates the link between Oncology and topics such as Proportional hazards model that cross with problems in Bevacizumab. In DNA methylation, Wolfgang Wick works on issues like Pathology, which are connected to Gene panel.
Wolfgang Wick mainly investigates Internal medicine, Glioma, DNA methylation, Oncology and Pathology. The various areas that he examines in his Internal medicine study include Gastroenterology and Glioblastoma. His study on Glioma is covered under Cancer research.
The concepts of his Cancer research study are interwoven with issues in Gene expression and Immune system. His Oncology research integrates issues from O-6-methylguanine-DNA methyltransferase, Clinical trial, Cerebrospinal fluid and Spinal muscular atrophy. His Pathology research incorporates elements of Gene panel, Dna methylation profiling and YAP1.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson.
The New England Journal of Medicine (2014)
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm;Hendrik Witt;Hendrik Witt;Volker Hovestadt;Dong Anh Khuong-Quang.
Cancer Cell (2012)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann;Christian Hartmann;Jochen Meyer;Jörg Balss;David Capper.
Acta Neuropathologica (2009)
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin.
Nature Medicine (2002)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick;Michael Platten;Christoph Meisner;Joerg Felsberg.
Lancet Oncology (2012)
DNA methylation-based classification of central nervous system tumours
David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels.
Journal of Clinical Oncology (2009)
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
Monika E. Hegi;Lili Liu;James G. Herman;Roger Stupp.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: